Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




A Liquid Biopsy Approach for Predicting Likely Relapse Following Treatment of Medulloblastoma in Children

By LabMedica International staff writers
Posted on 02 Nov 2021
A liquid biopsy technique that determines the level of cell-free DNA in cerebrospinal fluid (CSF) can be used to detect measurable residual disease (MRD) in children being treated for the malignant brain tumor medulloblastoma.

Nearly one-third of children with medulloblastoma die from the disease. More...
Conventional drug response monitoring by imaging and CSF cytology remains challenging, while a biomarker for MRD has not been found. MRD, which is the major cause of disease relapse, is the label for the small number of cancer cells that remain in the patient during treatment, or after treatment when the patient is in remission.

Investigators at St. Jude Children’s Research Hospital (Memphis, TN, USA) recently reported that they had identified a biomarker for medulloblastoma MDR. To do this, they used a liquid biopsy technique to acquire samples of cell-free DNA from the patients’ CSF combined with low-coverage whole-genome sequencing, which characterized the type of mutation called genome-wide copy number variation.

For this study, they analyzed serial CSF samples collected from children with medulloblastoma (123 patients, 476 samples) enrolled in a prospective trial. Results revealed that MRD was detected at baseline in 85% and 54% of patients with metastatic and localized disease, respectively. The number of MRD-positive patients declined with therapy, yet those with persistent MRD had significantly higher risk of progression. Importantly, MRD detection by the liquid biopsy method preceded radiographic progression in half the patients who relapsed.

“We scan patients frequently for the first couple of years when they come off therapy, but unfortunately, by the time we see a recurrence on a scan there is already a lot of disease,” said senior author Dr. Giles Robinson, a neuro-oncologist at St. Jude Children’s Research Hospital. “Relapsed medulloblastoma harbors an incredibly poor prognosis and for many it is too late to cure. As a result, we sought a better way to determine whether a child is truly clear of disease at the time they come off therapy. With this test, we now know that if there is medulloblastoma cell-free DNA in the CSF at the end of therapy, then that patient is very likely to relapse. That gives us something we can act on, an opportunity to truly eradicate the disease before it has had a chance to relapse or re-emerge.”

The medulloblastoma MRD study was published in the October 21, 2021, online edition of the journal Cancer Cell.

Related Links:
St. Jude Children’s Research Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.